

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Harris *et al.*

Application No. 10/502,431

Filed: July 22, 2004

Confirmation No. 3960

For: NEW TUMOR SUPPRESSOR GENE,
P28ING5

Examiner: Mark Halvorson

Art Unit: 1642

Attorney Reference No. 4239-64141-02

FILED VIA EFS

SUBMITTED VIA ELECTRONIC FILING SYSTEM
COMMISSIONER FOR PATENTS

TRANSMITTAL LETTER

Submitted for filing in the above-referenced application are the following:

- ☒ In connection with issuance of a patent:
 - ☒ Form PTOL-85b
 - ☒ Advance order of 4 copies (Fee \$3.00 each = \$12.00)
 - ☒ Issue Fee (\$1440.00)
 - ☒ Publication Fee (\$300.00)
- ☒ \$1,752.00 is being submitted herewith via EFS.
- ☒ The Director is hereby authorized to charge any additional fees that may be required in connection with issuance of a patent, or credit over-payment, to Account No. 02-4550.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Karri Kuenzli Bradley/
Karri Kuenzli Bradley, Ph.D.
Registration No. 56,300

cc: Docketing